21 – 30 of 33
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2007
-
Mark
Estrogen receptor beta expression is associated with tamoxifen response in ER alpha-negative breast carcinoma
(
- Contribution to journal › Article
- 2004
-
Mark
Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy
(
- Contribution to journal › Article
-
Mark
Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy : location, treatment, and outcome
(
- Contribution to journal › Article
-
Mark
Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy
(
- Contribution to journal › Article
- 2003
-
Mark
Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer
2003) In Journal of clinical oncology : official journal of the American Society of Clinical Oncology 21(20). p.43-3737(
- Contribution to journal › Article
-
Mark
Pharmacokinetics of intraperitoneal mitomycin C
(
- Contribution to journal › Scientific review
- 2001
-
Mark
A systematic overview of chemotherapy effects in ovarian cancer
(
- Contribution to journal › Scientific review
- 2000
-
Mark
Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument
2000) In Annals of oncology : official journal of the European Society for Medical Oncology 11(3). p.8-281(
- Contribution to journal › Article
-
Mark
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer : a randomised trial
(
- Contribution to journal › Article
-
Mark
ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer
2000) In Annals of oncology : official journal of the European Society for Medical Oncology 11(12). p.1545-1550(
- Contribution to journal › Article